The APPROACH clinical trial produces positive results with a mosaic HIV-1 vaccine

In a recent study published in The Lancet, results from a Phase I/IIa clinical trial demonstrated a novel mosaic HIV-1 vaccine candidate was well-tolerated and induced comparable and robust immune responses in healthy adults and rhesus monkeys, whilst also protecting monkeys against challenge with an HIV-like virus.

“This study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine candidate induced robust immune responses in humans and monkeys with comparable magnitude, kinetics, phenotype, and durability and also provided 67% protection against viral challenge in monkeys,” explained lead author Dan Barouch from Harvard (MA, USA), however, he noted that the results “should be interpreted cautiously.”

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment